Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wenyang Jieyu granules is a traditional Chinese medicine (TCM) formulation currently under clinical investigation for the treatment of rheumatoid arthritis (RA). Developed by the Beijing Municipal Health Commission, it is specifically targeted at patients exhibiting the TCM pattern of 'cold dampness obstruction and depression.' The formulation is administered as an oral granule, typically used as an adjunct to standard-of-care methotrexate. In clinical trials, it is evaluated for its ability to improve symptoms and disease activity in RA patients over a 12-week period. As a botanical preparation, its specific chemical constituents and biological targets are not fully characterized in public literature, but it is classified within the herbal/botanical modality.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Wenyang Jieyu granules.